XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
product_target
$ / shares
shares
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2022
USD ($)
material_right
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Accounts receivable     $ 7,026     $ 3,678
General and administrative expense     18,136 $ 14,908    
Biogen MA, Inc.            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Change in estimate of transaction price, increase in revenue     127,100      
Biogen MA, Inc. | License and Service            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Fixed consideration   $ 204,600        
Number of material rights expired | material_right           1
Number of material rights outstanding | material_right           7
Remaining performance obligation amount     1,700     $ 151,300
General and administrative expense     2,600 $ 100    
Biogen MA, Inc. | Stock Purchase Agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Sale of stock, number of shares issued in transaction (in shares) | shares   24,420,157        
Sale of stock, price per share (in dollars per share) | $ / shares   $ 9.2137        
Consideration received on transaction   $ 225,000        
Sale of stock, excess consideration received on transaction   79,600        
Collaboration agreement, equity issued   145,400        
Accounts receivable     700     500
Deferred revenue     1,500     $ 132,200
Net pension losses         $ 2,900  
Biogen MA, Inc. | Collaboration And License Agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Proceeds from collaborators $ 125,000 $ 125,000        
Number of neurological disease gene targets selected by counterparty (in product targets) | product_target   4        
Number of additional neurological disease gene targets (in product targets) | product_target   7        
Financial advisory fees         $ 7,000  
Percent of initial recognition   2.00%        
Contract with customer, asset, after allowance for credit Loss     $ 4,100